RNAC Q1 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10,000

Gross Profit

$10,000100.0% margin

Operating Income

-$12M-118560.0% margin

Net Income

-$12M-120740.0% margin

EPS (Diluted)

$-9.42

QoQ Revenue Growth

-98.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$62M

Total Liabilities

$48M

Stockholders' Equity

$15M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10,000	$0	—
Gross Profit	$10,000	$0	—
Operating Income	-$12M	-$16M	+25.0%
Net Income	-$12M	-$16M	+24.0%